Dr Richardson discusses his study on the use of melphalan flufenamide plus dexamethasone for the treatment of relapsed/refractory MM.

Dr Stull discusses the INSIGHT MM observational study examining ixazomib plus lenalidomide and dexamethasone for relapsed/refractory MM.

In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.

In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.

Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.

Joseph Mikhael, MD, MEd, FRCPC, Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, Discusses results from the IKEMA study.

Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.

Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.